AWTTC

All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

NICE and AWMSG Approved Medicines Formulary Status Report

(From 01 July 2025 to 30 June 2026)



BACKGROUND

The seven health boards and one NHS trust in Wales, are required to make recommended medicines available as soon as is reasonably practicable, and certainly within 60 calendar days of the publication of the decision. For National Institute for Health and Care Excellence (NICE) recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD)/Final Draft Guideline (FDG), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For All Wales Medicines Strategy Group (AWMSG) recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60-day timescale may be delayed. In such circumstances the 'Start date' aligns with the date that the delaying reason has been resolved. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

A formulary is an official list of medicines which may be prescribed within the health board or NHS trust to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use. Velindre University NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All medicines listed in this report were recommended over a 12-month period, commencing at least 14 months prior to the publication of this report. This is to account for the generally applicable 60-day period available to health boards and NHS trust to add these medicines to their formularies. Where an extended timescale has been authorised the data reporting system has been adapted to accommodate the variations.

SOURCE OF INFORMATION

This report has been compiled through an analysis of health board and trust submitted data to the All Wales Therapeutics and Toxicology Centre (AWTTC).

In exceptional circumstances some medicines data have been removed from this report in light of specific factors outside the control of health boards and NHS trust.

Data extracted 14/10/2026

Key					
	On formulary within required timescale		On formulary outside of required timescale		Not on formulary but within required timescale
	Not on formulary and outside of required timescale		Not applicable to Velindre		

Table 1. Formulary status for NICE and AWMSG approved medicines

Reference	Medicine Name	Abbreviated Indication	Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6274 (TA1079)	Fruquintinib	Colorectal cancer	03 Jul 25								
ID6293 (TA1042)	Selpercatinib	Lung cancer	04 Jul 25								
ID6328 (TA1060)	Osimertinib	Lung cancer	08 Jul 25								
ID6153 (TA1086)	Ribociclib	Breast cancer	18 Jul 25								
ID6462 (TA1087)	Betula verrucosa	Allergic rhinitis and/or conjunctivitis	21 Jul 25								
ID6308 (TA1074)	Sparsentan	Primary IgA nephropathy	23 Jul 25								
ID2725 (TA1090)	Tremelimumab	Hepatocellular carcinoma	29 Jul 25								
ID547 (TA1093)	Idebenone	Leber's hereditary optic neuropathy	08 Aug 25								
ID2725 (TA1090)	Durvalumab	Hepatocellular carcinoma	12 Aug 25								
ID6237 (ID1094)	Guselkumab	Ulcerative colitis	14 Aug 25								
ID6238 (TA1095)	Guselkumab	Crohn's disease	14 Aug 25								
ID5100 (TA1055)	Rucaparib	Ovarian, fallopian tube and peritoneal cancer	19 Aug 25								
ID3981 (TA1098)	Isatuximab	Multiple myeloma	04 Sept 25								
ID5073 (TA1099)	Durvalumab	Lung cancer	16 Sept 25								
ID6394 (TA1101)	Garadacimab	Hereditary angioedema	18 Sept 25								
ID4069 (TA1007)	Rucaparib	Ovarian, fallopian tube or peritoneal cancer	23 Sept 25								
ID6408 (TA1107)	Delgocitinib	Eczema	16 Oct 25								
ID6255 (TA1106)	Cabotegravir	HIV	17 Oct 25								
ID6452 (TA1109)	Darolutamide	Prostate cancer	24 Oct 25								
ID6378 (TA1110)	Abiraterone	Prostate cancer	30 Oct 25								
ID6372 (TA1085)	Vanzacaftor-tezacaftor-deutiva..	Cystic fibrosis	31 Oct 25								
ID6434 (TA1103)	Lorlatinib	Lung cancer	31 Oct 25								
ID6332 (TA1097)	Enfortumab vedotin	Urothelial cancer	07 Nov 25								
ID6332 (TA1097)	Pembrolizumab	Urothelial cancer	07 Nov 25								
ID6381 (TA1092)	Pembrolizumab	Endometrial cancer	07 Nov 25								
ID6202 (TA1113)	Glofitamab	Large B-cell lymphoma	14 Nov 25								
ID5082 (TA1114)	Talquetamab	Multiple myeloma	17 Nov 25								
ID6347 (TA1116)	Obecabtagene autoleucel	B-cell acute lymphoblastic leukemia	25 Nov 25								
ID6266 (TA1096)	Benralizumab	Eosinophilic granulomatosis	09 Dec 25								

Reference	Medicine Name	Abbreviated Indication	Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6294 (TA1120)	Axitinib	Renal cell carcinoma	11 Dec 25								
ID6354 (TA1121)	Acoramidis	Amyloidosis cardiomyopathy	12 Dec 25								
ID6291 (TA1119)	Obinutuzumab	Chronic lymphocytic leukamia	16 Dec 25								
ID6291 (TA1119)	Venetoclax	Chronic Lymphocytic Leukamia	16 Dec 25								
ID6256 (TA1122)	Amivantamab	Non small cell lung cancer	18 Dec 25								
ID6256 (TA1122)	Lazertinib	Non small cell lung cancer	18 Dec 25								
ID6369 (TA1126)	Natalizumab	Multiple Sclerosis	02 Jan 26								
ID6310 (TA1127)	Nivolumab	Non small cell lung cancer	20 Jan 26								
ID6415 (TA1117)	Dostarlimab	Endometrial cancer	22 Jan 26								
ID6420 (TA1131)	Obinutuzumab	Lupus nephritis	22 Jan 26								
ID6485 (TA1128)	Budesonide	IgA nephropathy	22 Jan 26								
ID4004 (TA1130)	Enzalutamide	Prostate Cancer	23 Jan 26								
ID4004 (TA1130)	Talazoparib	Prostate Cancer	23 Jan 26								
ID6211 (TA1133)	Belantamab mafodotin	Multiple Myeloma	23 Jan 26								
ID6211 (TA1133)	Pomalidomide	Multiple Myeloma	23 Jan 26								
ID6403 (TA1129)	Niraparib	Ovarian or fallopian tube or peritoneal cancer	26 Jan 26								
ID6470 (TA1115)	Vutrisiran	Cardiomyopathy	29 Jan 26								
ID6377 (TA1054)	Ruxolitinib	Graft versus host disease	02 Feb 26								
ID6465 (TA1136)	Bevacizumab	Colorectal cancer	06 Feb 26								
ID6338 (TA1139)	Epcoritamab	Follicular lymphoma	23 Feb 26								
ID6168 (TA1138)	Durvalumab	Bladder cancer	24 Feb 26								
ID6235 (TA1142)	Dupilumab	Chronic obstructive pulmonary disease	05 Mar 26								
ID6480 (TA1134)	Dupilumab	rhinosinusitis with nasal polyps	05 Mar 26								
ID5071 (TA1143)	Fezolinetant	Menopause	11 Mar 26								
ID6652 (TA1140)	Ruxolitinib	Vitiligo	12 Mar 26								
ID6477 (TA1145)	Pembrolizumab	Head and neck squamous cell carcinoma	24 Mar 26								
ID4029 (HST35)	Pegzilarginase	Arginase-1 deficiency	25 Mar 26								
ID6407 (TA1147)	Vorasidenib	Astrocytoma or oligodendroglioma	31 Mar 26								
ID6496 (TA1146)	Ripretinib	Gastrointestinal stromal tumours	31 Mar 26								
ID6441 (TA1152)	Semaglutide	Cardiovascular disease and overweight or obesity	01 Apr 26								
ID6439 (TA1148)	Sodium zirconium cyclosilicate	Hyperkalaemia	13 Apr 26								
ID6177 (TA1150)	Encorafenib	Non-small-cell lung cancer	21 Apr 26								
ID6388 (TA1153)	Zanidatamab	Biliary tract cancer	21 Apr 26								
ID5092 (TA1155)	Rozanolixizumab	Myasthenia gravis	29 Apr 26								
ID5110 (TA1158)	Amivantamab	Lung cancer	08 May 26								

Reference	Medicine Name	Abbreviated Indication	Start Date	Aneurin Bevan	Betsi Cadwaladr	Cardiff and Vale	Cwm Taf Morgannwg	Hywel Dda	Powys	Swansea Bay	Velindre
ID6163 (TA1161)	Sotatercept	Pulmonary arterial hypertension	14 May 26								
ID6195 (TA1162)	Risdiplam	Spinal muscular atrophy	14 May 26								
ID6619 (TA1159)	Lisocabtagene maraleucel	lymphoma	19 May 26								
ID3753 (TA1164)	Tisotumab vedotin	Cervical cancer	21 May 26								
4507	Budesonide	Eosinophilic esophagitis	26 May 26								
ID6223 (TA1156)	Osimertinib	Lung cancer	27 May 26								
ID6374 (TA1160)	Durvalumab	Gastric and gastro-oesophageal junction cancer	27 May 26								
ID1237 (TA1166)	Mepolizumab	Chronic obstructive pulmonary disease	28 May 26								
ID6346 (TA1167)	Serplulimab	Lung cancer	29 May 26								
ID6429 (TA1171)	Seladelpar	Primary biliary cholangitis	04 Jun 26								
ID6442 (TA1169)	Mirvetuximab soravtansine	Ovarian, fallopian tube or primary peritoneal cancer	04 Jun 26								
4742	Emicizumab	Haemophilia A	05 Jun 26								
ID6615 (TA1172)	Atogepant	Migraine	10 Jun 26								
ID6294 (TA1120)	Avelumab	Renal cell carcinoma	11 Jun 26								
ID6195 (TA1162)	Nusinersen	Spinal muscular atrophy	12 Jun 26								
ID6323 (TA1157)	Givinostat	Duchenne muscular dystrophy	12 Jun 26								
ID6269 (TA1173)	Pirtobrutinib	Lymphocytic leukaemia	16 Jun 26								
ID6487 (TA1175)	Glycopyrronium bromide cream	Axillary hyperhidrosis	19 Jun 26								
ID6259 (TA1176)	Teplizumab	Diabetes	23 Jun 26								
ID6610 (TA1174)	Cemiplimab	Cervical cancer	23 Jun 26								
ID6138 (TA1177)	Pembrolizumab	Cervical cancer	25 Jun 26								
ID6177 (TA1150)	Binimetinib	Non-small-cell lung cancer	29 Jun 26								

End of Report